Global Antivirals Market Insights 2024, Forecast To 2033
8 Jan, 2024
The antivirals market has shown robust growth, increasing from $97.72 billion in 2023 to $105.73 billion in 2024, with an 8.2% CAGR. Factors like viral disease prevalence, public health concerns, patent expirations, and government initiatives fueled historic period growth. Forecasts suggest continued expansion, reaching $143.83 billion in 2028, with an 8.0% CAGR. Drivers include emerging viral threats and global health initiatives, accompanied by trends like technological advances and personalized medicine.
Global Antivirals Market Key Driver
The rising incidence of influenza is set to drive the antiviral market's growth. Influenza, or flu, a contagious viral respiratory infection, affects the nose, throat, and lungs. Antivirals, designed to hinder influenza virus replication, are crucial for treatment. In the 2021-2022 season, the Centers for Disease Control and Prevention reported 9 million flu illnesses, 4 million medical visits, 100,000 hospitalizations, and 5,000 deaths. This upswing in influenza incidents propels the antiviral market's growth.
Get A Free Sample Of The Global Antivirals Market ReportGlobal Antivirals Market Segments
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
By Geography: The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Antivirals Industry Players
AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
Get The Full Global Antivirals Market Report
Antivirals Market Overview
Anti-viral drug therapy refers to drugs that are used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, influenza, and novel coronavirus. Antiviral drugs do not kill their target pathogens, instead, they inhibit the development of those viruses. The anti-viral drug establishments are primarily engaged in the manufacturing of DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.
Antivirals Global Market Report 2023 provides data on the global antivirals market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The antivirals market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.